Back to Peptides

PT-141

FDA Approved

Melanocortin Receptor Agonist | Sexual Dysfunction Treatment

Dose Women: 1.75mg (FDA-approved); Men: 1-2mg; Start 0.5mg test dose for tolerance
Frequency As needed before sexual activity; max 1 dose per 24 hours
Cycle Use as needed for sexual enhancement
Storage Refrigerate at 2-8°C, use reconstituted solution within 30 days
Accumulation Plotter

FDA-approved melanocortin receptor agonist for treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Works centrally in the nervous system to trigger sexual arousal pathways independent of vascular mechanisms, unlike traditional ED medications.

Mechanism of Action

Selectively activates melanocortin receptors (MC3R/MC4R) in the central nervous system, triggering sexual arousal pathways independent of peripheral vascular mechanisms. Works within 45 minutes with effects lasting 6-12 hours.

Key Benefits

  • FDA-approved pharmaceutical route
  • Predictable absorption profile
  • Effective for both male and female sexual dysfunction
  • Works within 45 minutes
  • Effective in PDE5 inhibitor-resistant cases
  • Central mechanism (not dependent on blood flow)
Type
Melanocortin receptor agonist

Sexual Health

  • Hypoactive Sexual Desire Disorder (HSDD)

    FDA-approved for treatment of HSDD in premenopausal women.

  • Erectile Dysfunction

    Effective in men including PDE5 inhibitor-resistant cases via CNS pathways.

  • Female Sexual Arousal Disorder

    Enhances sexual arousal and desire in women.

Quality of Life

  • Sexual Distress Reduction

    Reduces distress related to low sexual desire.

  • Sexual Satisfaction

    Enhanced satisfaction reported in clinical trials.

Subcutaneous injection is the FDA-approved route. Administered 45-60 minutes before anticipated sexual activity.

GoalDoseFrequencyRoute
Female HSDD (FDA-approved)1.75mgAs needed, max 1 dose/24hrSubQ
Male Erectile Dysfunction1-2mgAs needed, 45-60min before activitySubQ
Female Arousal Disorder0.75-1.25mgAs needed, max 1 dose/24hrSubQ
Low Starting Dose0.5mgTest dose for tolerance assessmentSubQ

Reconstitution Instructions

Materials Needed:
  • PT-141 lyophilized powder vial
  • Bacteriostatic water (1-2mL)
  • Insulin syringe (29-31 gauge)
  • Alcohol swabs
  • Sterile mixing syringe
  1. 1 Allow vial to reach room temperature (15-20 minutes)
  2. 2 Clean vial tops with alcohol swabs
  3. 3 Draw 1-2mL bacteriostatic water
  4. 4 Inject BAC water slowly down vial side
  5. 5 Gently swirl until fully dissolved (do not shake)
  6. 6 Solution should appear clear and colorless
  7. 7 Store reconstituted solution refrigerated
  8. 8 Use within 30 days of reconstitution
Sildenafil/Tadalafil

PT-141 works centrally; PDE5 inhibitors work peripherally - monitor for additive BP effects.

monitor
Melanotan II

Both are melanocortin agonists; combining risks excessive activation and side effects.

monitor
Blood Pressure Medications

PT-141 can transiently lower blood pressure - monitor closely.

monitor
Alcohol

Both lower BP and cause flushing - limit intake to avoid excessive hypotension.

monitor
Nitrates

Risk of severe hypotension - contraindicated with heart condition medications.

avoid
BPC-157

Different mechanisms; no known interactions.

compatible
Testosterone

May work synergistically for sexual dysfunction through different pathways.

synergistic
Kisspeptin

Different pathways (melanocortin vs GnRH) - no receptor overlap but monitor BP effects.

monitor
0-30 minutes

Mild nausea or facial flushing possible

45-90 minutes

Onset of effects - increased arousal and desire

2-4 hours

Peak effects - enhanced sexual response

6-12 hours

Gradual diminishment of effects

Common Side Effects

  • Nausea (40%)
  • Flushing (20%)
  • Headache (11%)
  • Injection site reactions

Stop Signs - Discontinue if:

  • Severe or persistent nausea/vomiting
  • Significant blood pressure drop or dizziness
  • Chest pain or irregular heartbeat
  • Severe headache or vision changes
  • Prolonged erection exceeding 4 hours

Contraindications

  • Uncontrolled hypertension
  • Cardiovascular disease
  • Use of nitrate medications
  • Pregnancy or breastfeeding

Good Signs

  • FDA-approved pharmaceutical grade (Vyleesi) from licensed pharmacy
  • White crystalline powder (pure PT-141)
  • Clear solution when reconstituted
  • Proper labeling with concentration and purity

Warning Signs

  • Compounded versions - ensure pharmacy is licensed and follows USP standards

Bad Signs

  • Colored or oily appearance indicating impurities or degradation
  • Cloudy solution after reconstitution
  • Unknown source without quality documentation
  • FDA Approval Trial for HSDD
    (2019)

    Phase 3 trials with 1.75mg subcutaneous in premenopausal women showed 24.5% improvement vs 17.2% placebo, achieving statistical significance.

  • Male Erectile Dysfunction Clinical Trial
    (2017)

    1-20mg intranasal showed dose-dependent erectile response, effective including in PDE5 inhibitor-resistant cases via CNS pathways.

  • Mechanism of Action Study
    (2016)

    In vitro and animal studies confirmed selective MC3R/MC4R binding activating sexual arousal without peripheral vasodilation.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.